COZEN O'CONNOR

October 24, 2018

Meridith Moldenhauer
Direct Phone 202-747-0763
Direct Fax 202-683-9389
mmoldenhauer@cozen.com

Frederick L. Hill, Chairperson
Board of Zoning Adjustment
441 4th Street, NW, Suite 200S
Washington, DC 20010

Re: BZA Case No. 19751
Applicant's Supplemental Prehearing Statement

Chairperson Hill and Honorable Members of the Board:

On behalf of Applicant MED Developers, LLC, please find enclosed a supplemental prehearing statement. The hearing on this application was previously continued by the Board from September 26, 2018 to November 14, 2018. Accordingly, we look forward to presenting the application to the Board on November 14, 2018.

Thank you for your attention to this matter.

Sincerely,

COZEN O'CONNOR

BY: Meridith H. Moldenhauer

CERTIFICATE OF SERVICE

I hereby certify that on this 24th day of October, 2018, a copy of the foregoing Applicant's Supplemental Prehearing Statement was served, via electronic mail, on the following:

District of Columbia Office of Planning
c/o Brandice Elliott
1100 4th Street SW, Suite E650
Washington, DC 20024
Brandice.Elliott@dc.gov

Advisory Neighborhood Commission 3C
c/o Nancy MacWood, Chairperson
nmacwood@gmail.com

Massachusetts Avenue Heights Citizens' Association
c/o Paul Cunningham, Anita Crabtree, and Andrea Ferster
pac@harkinscunningham.com
anitaliviamitra@yahoo.com
aferster@railstotrails.org

Meridith H. Moldenhauer

BEFORE THE DISTRICT OF COLUMBIA
BOARD OF ZONING ADJUSTMENT

APPLICATION OF **BZA CASE NO. 19751**
MED DEVELOPERS, LLC **HEARING DATE: NOVEMBER 14, 2018**

APPLICANT'S SUPPLEMENTAL PREHEARING STATEMENT

I. INTRODUCTION

This Supplemental Prehearing Statement is submitted on behalf of the Applicant MED Developers, LLC (the "Applicant") pursuant to the Board's request during a hearing on this application on September 26, 2018. The party-in-opposition, Massachusetts Avenue Heights Citizens' Association ("MAHCA"), identified three expert witnesses in its supplemental filing, but offered no further information or evidence for the Board. *See* BZA Ex. No. 318.

Accordingly, in this document, the Applicant will detail the following supplemental information:

-MAHCA's claim regarding "viability" of Project's proposed use is not germane to the special exception standard
-Applicant's second parking study with TDM plan from Gorove/Slade
-Identification of additional expert/rebuttal witnesses
-Clarification on letters of opposition

In addition to this filing, the Applicant has established in the initial application (BZA Ex. No. 15) as well as the Prehearing Statement (BZA Ex. No. 41) that the Applicant satisfies the special exception standard for a Continuing Care Retirement Community use and for vehicular parking to construct a 34-unit memory care facility (the "Project") at 2619-2623 Wisconsin Avenue NW (the "Property").

II. MAHCA'S CLAIM REGARDING "VIABILITY" OF PROPOSED USE IS NOT GERMANE TO THE SPECIAL EXCEPTION STANDARD

Despite providing no evidence to supports its claim, MAHCA argues that the Applicant's proposed memory care use is not "commercially viable." *See* BZA Ex. No. 43A, pg. 8. MAHCA offers no legal basis for its claims that "viability" should be a factor in the Board's deliberations

on the CCRC use special exception. Simply put, unsubstantiated allegations attacking the "viability" of a proposed use are not germane to the special exception standard.

It is well-established that the Board's evaluation of a special exception "is limited to a determination whether the exception sought meets the requirements of the particular regulation on which the application is based." *See President & Dirs. Of Georgetown College v. D.C. Bd. of Zoning Adjustment*, 837 A.2d 58, 68 (2003). Once an applicant has met the specific requirements for the special exception "the Board ordinarily must grant the application." *See id.*

Here, the special exception standard for a Continuing Care Retirement Community ("CCRC") use requires the Applicant to demonstrate that the CCRC use: (1) "will be in harmony with the general purpose and intent of the Zoning Regulations"; and (2) "will not tend to affect adversely, the use of neighboring property in accordance with the Zoning Regulations and Zoning Maps." *See* Subtitle X § 901.2. Further, the Applicant must show that it has met the six special conditions for a CCRC use as set forth under Subtitle U § 203.1(f). However, the "viability" of the Project's proposed CCRC use is not a required condition under the general special exception standard *or* the special conditions for a CCRC use.

The Board has routinely disregarded opposition arguments that are outside the Board's statutory purview under D.C. Code § 6-641.07. The Board has held that whether a proposed use is "best" for a particular property "is not germane to the Board's deliberation." *See* BZA Case No. 18924, Order, pg. 6. The Board previously stated that whether a house will be "renter- or owner-occupied" is not relevant to its zoning determination. *See* BZA Case No. 17949, Order, pg. 6. Likewise, a community's request that the unbuilt portion of a site be used for residential purposes was found by the Board to not be germane to a zoning application. *See* BZA Case No. 13317, pg. 6. The Board has rejected other arguments concerning construction and the building code,

environmental impacts and stormwater management as outside the scope of zoning review. *See* BZA Case Nos. 18943, 19211, 16457, 17679.[1]

Notwithstanding that MAHCA's viability argument is not germane to the special exception standard, the record reflects that the Project has been developed and designed in a way that best suits the unique needs of seniors with dementia. The Applicant has detailed specific design features of the proposed Project, including, but not limited to, safety and security features, promotion of privacy, encouragement of on-site recreational and therapeutic activities. *See* BZA Ex. No. 41.

The Applicant has also detailed the involvement of Guest Services Senior Living as the operator of the proposed memory care facility, and how Guest Services Senior Living's expertise in the field contributed to the development of a well thought-out Project. *See* BZA Ex. No. 41. The record reflects the experience of John Gonzales, President of Guest Services Senior Living, in operating and managing assisted living facilities, and Claire Dickey, the project architect from Perkins Eastman, in designing assisted living facilities. *See* BZA Ex. No. 41A, Tabs C, D. Importantly, the Applicant has identified Mr. Gonzales and Ms. Dickey as expert witnesses to testify at the hearing before the Board in order to provide additional information regarding the "viability" of the proposed Project and the wealth of experience and knowledge possessed by the Applicant's team. Finally, as outlined in **Section IV** herein, two additional expert witnesses will be available to testify if needed on rebuttal for the Applicant; these witnesses can contribute expert testimony that will speak directly to these issues.

[1] Similarly, as part of a modification to the "Watergate" PUD, the Zoning Commission rejected an opposition party's argument that the applicant was "unable to carry out the plan for which it sought approval" because a business licensing issue was "outside the Commission's purview," and "not a land use matter." *See* ZC Case No. 13-06, Order, pg. 18.

III. PARKING STUDY

As part of the subject application, the Applicant is requesting special exception relief from the minimum requirement for vehicular parking pursuant to Subtitle C § 703.2. In support of this relief, the Applicant has submitted a parking study (the "First Parking Study") and a supplemental memorandum from Gorove/Slade, the Applicant's traffic expert. *See* BZA Ex. Nos. 39, 107. Gorove/Slade has now conducted a second parking study (the "Second Parking Study"). The Second Parking Study was conducted in order to reiterate the conclusion that the Project will provide sufficient off-street parking to meet the needs of the Project's employees, residents and visitors. A copy of the Second Parking Study is attached at **Tab A**.[2] Based on the abundance of on-street parking, it is Gorove/Slade's expert conclusion that the Project's nine parking spaces are sufficient.

In response to unfounded allegations from the community, Gorove/Slade conducted the study for two additional days of the week. Similar to the First Parking Study, Gorove/Slade found that there is an excess of on-street parking in the vicinity of the proposed Project on both Sunday and Tuesday. *See* **Tab A**, pg. 1. Specifically, Gorove/Slade found that on a typical Sunday or Tuesday there is at least 106 available parking spaces within two blocks of the Property. *See* **Tab A**, pg. 1. The highest demand and utilization rate on Sunday is 65% and the highest demand and utilization rate on Tuesday is only 63%. *See* **Tab A**, pg. 2-4. Notably, Gorove/Slade found parking availability for unrestricted (non-RPP and non-time-restricted) spaces as well. *See* **Tab A**, pg. 4. Accordingly, as in the First Parking Study, Gorove/Slade concludes that there is sufficient on-street parking to adequately meet the demand created by the Project. *See* **Tab A**, pg. 5.

[2] Whereas the First Parking Study analyzed data collected on a Thursday and Saturday, the Second Parking Study analyzes parking data collected on a Sunday and Tuesday in the Property's vicinity.

In addition to the parking study, the Applicant has prepared and voluntarily proffered a Transportation Demand Management Plan ("TDM Plan") in the Second Parking Study. *See* **Tab A**, pg. 4-5. The Applicant proposes the following in the TDM Plan:

- The Applicant will identify TDM Leaders (for planning, construction, and operations). The TDM Leaders will work with employees in the development to distribute and market various transportation alternatives and options.
- The Applicant will work with DDOT and goDCgo (DDOT's TDM program) to implement TDM measures at the proposed development.
- The Applicant will share the full contact information of the TDM coordinator for the proposed development with DDOT and goDCgo.
- The Applicant will provide facility employees who wish to carpool with detailed carpooling information and will be referred to other carpool matching services sponsored by the Metropolitan Washington Council of Governments (MWCOG).
- The Applicant will install a Transportation Information Center Display (electronic screen) within the lobby of the building containing information related to local transportation alternatives.
- The Applicant will identify with nearby parking garage facilities that can provide additional parking for guests and employees.

The Applicant has now provided data from four different days, which establishes there is a sufficient supply of on-street parking to supplement the nine off-street parking spaces provided at the Project. In addition to the excess supply of on-street parking, the Applicant has highlighted a number of other factors that mitigate any adverse effects of the parking relief on neighboring properties, including, but not limited to, decreased demand due to the nature of the memory care use, good access to public transportation, staggered shifts for staff, the expected modal split for staff, the availability of paid parking garages in the nearby area, and the TDM Plan. *See* Ex. Nos. 39, 41, 107. Accordingly, the Second Parking Study underscores that the Applicant has met its burden for special exception relief from the minimum parking requirements.

IV. APPLICANT'S EXPERT WITNESSES

The Applicant previously designated four expert witnesses to testify in support of the subject application. *See* BZA Ex. No. 41, pg. 18. The Applicant's previous four expert witnesses include: (1) Stephen Varga, who will testify as an expert in land use and planning; (2) John Gonzales, who will testify as an expert in best practices for operating and managing assisted living facilities; (3) Claire Dickey, who will testify as an expert in architecture and design; and (4) Erwin Andres, who will testify as an expert in traffic and transportation.

In addition to these expert witnesses, the Applicant identifies the following two expert witnesses:

1. Thomas B. Gale, Senior Vice President at Lancaster Pollard, as an expert in financing for senior living and health care facilities. A copy of Mr. Gale's resume is attached at **Tab B**. Mr. Gale will testify regarding the viability of the Project from a capital financing perspective.
2. Dr. Jeffrey Keller, Chief Executive Officer at Keller-Lamar Health Foundation, as an expert in designing and implementing memory care programs and services. A copy of Dr. Keller's resume is attached at **Tab C**. Dr. Keller will testify regarding the overall need for memory care facilities as well as how the Project's proposed design meets best practices for memory care facilities.

V. LETTERS IN OPPOSITION

In regard to the opposition letters filed in the record, it is worth clarifying that MAHCA has employed a strategy to artificially flood the record and mislead as to the level of opposition to the Project. The form petitions filed in the record are generated through an online website that contains inaccurate information, which dilutes the value of these auto-filled petitions. As a result of this "one click" petition, it has become clear that many of those "in opposition" do not live in

the vicinity of the Property. Specifically, when excluding multiple letters filed from single households and duplicate letters from the same individual, only 25% are from individuals who live within the Single Member District for ANC 3C08.[3] The amount of individuals opposing the Project that do not live close to the Property is striking given that the petition makes various claims of highly localized impacts on "neighbors." Further, there are several individuals who have submitted multiple letters in the record as well as individuals from the same household submitting multiple letters. There are also several members of MAHCA who filed separate letters of opposition despite already requesting party status in this matter.

VI. CONCLUSION

We look forward to presenting this application to the Board on November 14, 2018 and discussing this Project that will address the needs of a vulnerable segment of the District's population. The Applicant and its team have worked diligently to develop a Project that is designed to meet the unique needs of seniors with dementia, and the presentation to the Board will reflect this extensive and thoughtful process.

Respectfully submitted,
COZEN O'CONNOR

Meridith H. Moldenhauer
1200 19th Street, NW
Washington, DC 20036
(202) 912-4800

[3] As of October 24, 2018 at 10:00 p.m.

Tab A

GOROVE / SLADE

1140 Connecticut Avenue NW
Suite 600
Washington, DC 20036
202.296.8625

TECHNICAL MEMORANDUM

To: Board of Zoning Adjustment

From: Vinay Varadarajan
Katie Wagner, PE, PTOE
Erwin Andres

Date: October 24, 2018

Subject: 2619-2623 Wisconsin Avenue NW BZA Supplemental Parking Study

INTRODUCTION

This memorandum presents the findings of a supplemental parking study conducted for the 2619-2623 Wisconsin Avenue, NW continuing care retirement community development in support of its Board of Zoning Adjustment (BZA) application (BZA Case Number 19751). The site is bound by Edmunds Street to the north, residential properties to the east and south, and Wisconsin Avenue to west as shown on Figure 1. This project consists of redeveloping the site which is comprised of a vacant lot and a single-family house. The proposed assisted living development will be a single three-story building containing approximately 34 dwelling units and nine (9) parking spaces in the rear of the building.

The proposed development includes a continuing care retirement community building in an R zone consisting of 34 dwelling units, which under current Zoning Regulations require 17 parking spaces. Given the nature of the development as an assisted living facility, most residents will not require on-site parking. Staff and visitors will be able to use the multimodal options serving the site as it is well served by Metrobus lines, car share, and bike share. The proposed parking and availability of parking in the area near the site would accommodate visitors. Additionally, providing the required number of spaces is impracticable given the depth of the site. As such, the Applicant is seeking special exception relief from the amount of parking required in the R-1-B zone.

A parking study dated May 18, 2018 (the "May 2018 Parking Study") inventoried on-street parking within a two-block radius of the site. The study was conducted on a typical Thursday and Saturday. The findings revealed that at any time during a typical weekday or weekend day, there were at least **103** parking spaces available within a two-block radius of the site, indicating that the observed supply of on-street parking options would adequately serve the project.

A supplemental parking study was commissioned to observe on-street parking occupancy on a typical Sunday and Tuesday. The following conclusions were made regarding the 2619-2623 Wisconsin Avenue development:

- The observed supply of on-street parking options will adequately serve the project on a typical Sunday and Tuesday.
- At any time during a typical Sunday or Tuesday, there are at least **106** parking spaces available within two (2) blocks of the subject site.
- A robust Transportation Demand Management (TDM) plan is proposed to further reduce the demand of single-occupancy vehicles.

Parking

As mentioned previously, nine (9) spaces are proposed for the development in the rear of the building. The site and its immediate vicinity sits within Zone 3 of the DC parking zone map. The May 2018 Parking Study established that the neighborhood surrounding the site currently has on-street parking availability on a typical Thursday and Saturday. While the May 2018 Parking study is sufficient to show adequate on-street parking availability, this study was prepared to refute ANC and community arguments regarding availability on other days of the week; accordingly, parking occupancy counts were conducted on Sunday, October 21, 2018 and Tuesday, October 23, 2018. The parking occupancy study consisted of hourly sweeps of nearby streets within a two-block radius of the site location between the hours of 10:00 AM and 5:00 PM on Sunday, the 21st and between 7:00 AM and 9:00 PM on Thursday, the 23rd. The times were selected to reflect times where a majority of staff will be on-site and weekend visitation for guests of residents. The results of the study indicate that the on-street parking spaces have the ability to accommodate any on-street parking demand that the proposed facility development may generate. The parking study area is shown on Figure 3.

A total of 333 spaces were inventoried in the study area. Parking restrictions by block are shown on Figure 4. As seen in the figure, some blocks along Wisconsin Avenue are subject to street sweeping regulations on Wednesdays and weekday peak-period restrictions. During the Sunday observations, an additional 48 parking spaces were available on Sunday for church services during the morning and early afternoon hours because on-street parking is allowed on both sides of Fulton Street, Edmunds Street, and Davis Street. Typically, on-street parking is only allowed on one side of these streets.

As shown in Figure 1, the highest demand and utilization of spaces observed in the Sunday parking sweep was during the 10:00 AM hour, where 218 (65%) of the 333 available parking spaces were occupied.

As shown in Figure 2 during the Tuesday sweep, the 7:00 AM hour observed the highest utilization of spaces where 179 (63%) of the 285 available spaces were occupied.



Figure 1: On-Street Parking Occupancy, Sunday, October 21, 2018



Figure 2: On-Street Parking Occupancy, Tuesday, October 23, 2018

The peak period utilization occupancy by block is shown on Figure 5 and Table 1 for Sunday, October 21 (10:00 AM). Figure 6 and Table 2 show the peak period utilization occupancy by block for Tuesday, October 23 (7:00 AM).

During the Sunday peak period, occupancies by block varied greatly, but generally the most densely occupied street parking blocks were the east side of Wisconsin Avenue between Davis and Fulton Streets. Most of the blocks with occupancy greater than 90 percent were observed on block faces with which had no restrictions on Sundays. Of the additional 48 parking spaces available for church services on Fulton Street, Edmunds Street, and Davis Street, seven (7) spaces were occupied during the peak period.

During the Tuesday peak period, areas of higher occupancy levels occurred along the west side of Wisconsin Avenue, east side of 36th Place, and along Calvert Street. These areas were a mixture of time-restricted parking (along Wisconsin Avenue), RPP-restricted parking (along 36th Place), and unrestricted parking (Calvert Street). All RPP parking spaces restrict non-residents to a two-hour limit from 7:00 AM to 8:30 PM from Monday to Friday.

As noted on Table 3**,** the peak period on Sunday generally showed parking occupancies ranging from 15% in restricted types of spaces, to 74% for unrestricted spaces. On Sundays, RPP and many weekday-only time restrictions are lifted, allowing for an additional 261 spaces to become unrestricted. Parking occupancies on Tuesdays vary from 58% to 79% between restricted and unrestricted spaces, respectively. Notably during the peak Tuesday period, none of the block faces inventoried had occupancies of 90 percent or more, indicating additional capacity for all parking types.

On Sunday, 65% of spaces were occupied during the peak occupancy period, with 63% occupied on Tuesday. Between the two days, a minimum of 106 spaces are available for use. Even during the highest occupancy periods, parking of all space types was readily available in the vicinity of the project site. These observations confirm the observed supply of available on-street parking can provide additional on-street parking spaces to help support the proposed development.

Table 1: Peak Parking Occupancy, Sunday, October 21, 2018

	AM		PM					
	10:00	11:00	12:00	1:00	2:00	3:00	4:00	5:00
Occupancy	218	200	196	177	170	169	178	169
Total Spaces	333	333	333	333	285	285	285	285
Utilization	65%	60%	59%	53%	60%	59%	62%	59%

Table 2: Peak Parking Occupancy, Tuesday, October 23, 2018

	AM					PM									
	7:00	8:00	9:00	10:00	11:00	12:00	1:00	2:00	3:00	4:00*	5:00*	6:00*	7:00	8:00	9:00
Occupancy	179	177	163	166	161	154	151	157	148	144	137	147	156	170	178
Total Spaces	285	285	285	285	285	285	285	285	285	251	251	251	285	285	285
Utilization	63%	62%	57%	58%	56%	54%	53%	55%	52%	57%	55%	59%	55%	60%	62%

*Peak-Period Restrictions along Wisconsin Avenue in effect during these periods.

Table 3: Peak Period Inventory and Occupancy Summary

Space Type	Sunday, Oct 21: Peak Period (10:00 AM)				Tuesday, Oct 23: Peak Period (7:00 AM)			
	Spaces	Occupancy	Utilization	Available	Spaces	Occupancy	Utilization	Available
Non-RPP (Time-Restricted)*	48	7	15%	41	56	42	75%	14
RPP*	--	--	--	--	205	118	58%	87
Unrestricted	285	211	74%	74	24	19	79%	5
Illegal Spaces	--	--	--	--	--	--	--	--
All On-Street Spaces	**333**	**218**	**65%**	**115**	**285**	**179**	**63%**	**106**

*Most time-restricted and all RPP restrictions are not in effect on Sundays

Transportation Demand Management (TDM) Plan

Transportation Demand Management is the application of policies and strategies used to reduce travel demand or to redistribute demand to other times or spaces. TDM elements typically focus on reducing the demand of single-occupancy, private vehicles during peak period travel times or on shifting single-occupancy vehicular demand to off-peak periods.

The TDM plan for the 2619-2623 Wisconsin Avenue, NW BZA development is based on DDOT expectations for TDM programs for developments of this type and size. As such, the Applicant proposes the following TDM measures:

- The Applicant will identify TDM Leaders (for planning, construction, and operations). The TDM Leaders will work with employees in the development to distribute and market various transportation alternatives and options.
- The Applicant will work with DDOT and goDCgo (DDOT's TDM program) to implement TDM measures at the proposed development.
- The Applicant will share the full contact information of the TDM coordinator for the proposed development with DDOT and goDCgo.
- The Applicant will provide facility employees who wish to carpool with detailed carpooling information and will be referred to other carpool matching services sponsored by the Metropolitan Washington Council of Governments (MWCOG).

- The Applicant will install a Transportation Information Center Display (electronic screen) within the lobby of the building containing information related to local transportation alternatives.
- The Applicant will identify nearby parking garage facilities that can provide additional parking for guests and employees.

Conclusions

This memorandum presents the findings of a supplemental parking study conducted for the 2619-2623 Wisconsin Avenue, NW development. The following conclusions were made:

- The observed supply of on-street parking options will adequately serve the project on a typical Sunday and Tuesday.
- At any time on a typical Sunday or Tuesday, there are at least **106** parking spaces available within two (2) blocks of the subject site.
- A robust Transportation Demand Management (TDM) plan is proposed to further reduce the demand of single-occupancy vehicles.



Figure 3: Parking Study Area



Figure 4: Parking Restrictions by Block Face



Figure 5: Sunday, October 21, 2018 Peak Period Street Parking Occupancy



Figure 6: Tuesday, October 23, 2018 Peak Period Street Parking Occupancy

Tab B

Financing Progress

LANCASTER POLLARD

Thomas B. Gale

Senior Vice President

Thomas B. Gale

(610) 989-9006
tgale@lancasterpollard.com

Thomas B. Gale is a senior vice president with Lancaster Pollard, a financial services firm based in Columbus, Ohio, that specializes in providing capital funding services to the health care and senior living sectors. In addition to underwriting tax-exempt bond offerings, Lancaster Pollard provides organizations a complete range of funding options through its Fannie Mae/FHA-HUD/GNMA/USDA-approved mortgage company. It can also provide bridge-to-agency lending, private equity, balance sheet lending and investing, and M&A services. Mr. Gale is the primary point of contact for clients in Virginia, Maryland, Delaware, West Virginia and Washington, D.C. and is responsible for assisting health care organizations with bond financings, mortgage placements, debt capacity planning and interest rate risk management.

Prior to joining Lancaster Pollard, Mr. Gale was a vice president of Sovereign Bank, where he had primary responsibility for the development and oversight of Sovereign's Eastern United States continuing care retirement community, senior living and health care portfolio. In total, he managed a portfolio of loans and commitments of $550 million. In addition, Mr. Gale has been involved in nearly a billion dollars of financings for health care and senior housing providers. Mr. Gale also has held health care lending positions with Ziegler Healthcare Capital and M&T Bank.

Tab C

CURRICULUM VITAE

Jeffrey N. Keller

Founder/Director of the Institute for Dementia Research and Prevention
Director of the Alzheimer's Disease Cooperative Study Site (Pennington Biomedical)
Professor, Hibernia National Bank/Edward G. Schlieder Chair
Pennington Biomedical Research Center
LSU System
6400 Perkins Road
Baton Rouge, Louisiana 70808-4124
Phone: (225) 763-3190
Fax: (225) 763-3193
E-mail: jeffrey.keller@pbrc.edu

PERSONAL

Date of Birth:	September 24, 1969
Place of Birth:	Owensboro, Kentucky
Family:	Married, two children (Hannah and Joel)

EDUCATION

B.S.	University of Kentucky, 1996 Biology
Ph.D.	University of Kentucky, 1998 Neuroscience (MCB)

PROFESSIONAL EXPERIENCE AND ACADEMIC APPOINTMENTS

1999-2000	Postdoctoral Fellow, Oxidative stress and Alzheimer's disease. Department of Neuropathology, University of Kentucky; Dr William R. Markesbery, mentor
2000-2001	Research Assistant Professor, Department of Biochemistry, University of Kentucky; Dr Louis B. Hersh, chairman
2001-2005	Assistant Professor, Department of Anatomy and Neurobiology, University of Kentucky; Dr Don Gash, chairman.
2005-2007	Associate Professor, Department of Anatomy and Neurobiology, University of Kentucky; Dr Don Gash, chairman.
2006-2008	R.C. Durr Endowed Chair for Alzheimer's Research
2007-2008	Assistant Director, Sanders-Brown Center on Aging, University of Kentucky: Dr William R. Markesbery, Director

2008-present Hibernia National Bank/Edward G. Schlieder Chair, Pennington Biomedical Research Center

2008-present Professor, Pennington Biomedical Research Center

2008-2012 Institutional Official, Pennington Biomedical Research Center

2008-2012 Associate Executive Director Basic Science, Pennington Biomedical

2008-present Adjunct Professor, School of Human Ecology, Louisiana State University

2008-present Appointed to Louisiana Alzheimer's Disease Task Force

2008-present Appointed to Louisiana Health Care Quality Forum, Outreach & Education Committee

2008-present Founder and Director, Institute for Dementia Research & Prevention, Pennington Biomedical Research Center

2012-present Adjunct Professor of Pharmacy Practice, Department of Pharmaceutical Sciences, University of Louisiana, Monroe

2014-present Site Director, Alzheimer's Disease Cooperative Study Site (Pennington Biomedical Research Center)

NON-ACADEMIC APPOINTMENTS

2013-Present Founder, Partner, and Chief Scientific Officer of Helping Hands Technology LLC.
2016-Present Executive Board Member of the YMCA (Greater Baton Rouge Area)
2017-Present CEO, Keller-Lamar Health Foundation

AWARDS AND HONORS

1999-2000	John Douglas French Foundation post-doctoral Fellowship for AD
1999-2000	American Heart Association post-doctoral Fellowship for Stroke
2000-2004	American Heart Association Young Investigator Award
2001-Present	National Advisory Council for American Federation of Aging Research
2001-2005	Wethington Research Excellence Award, University of Kentucky College of Medicine
2005	Awarded Fellowship to Participate in the National Institute of Aging "Training in Aging Research" Buck Institute, Novato Ca.
2004	Nominated for the *FEBS Letter* prize

CURRENT AND PREVIOUS GRANT FUNDING

American Health Assist Foundation (PI: Keller) 1999-2001
"Proteasome inhibition in AD"
This grant examined the impact of Beta-amyloid and AD pathogenesis to proteasome alterations in AD.

American Heart Association (PI: Keller) 1999-2001
"Involvement and Characterization of the Multicatalytic Proteasome in Ischemia Reperfusion Injury". Young Scientist Development Award (0030193N)
This grant funding in vivo and in vitro work in stroke looking at proteasome biology and proteasome pathogenesis.

HD Society of America/NINDS (PI: Keller) 2000-2002
"High throughput drug screening for HD"
This grant funded a high throughput screen for HD therapeutics using a neural model of polyglutamine toxicity.

R01 NS042111 (co-PI: Keller) 2001-2005
NIH/NINDS "Dopamine Toxicity in Models of Huntington's Disease"
This project examined the basis for oxidative stress mediated neural toxicity in animal and cell culture models of HD.

RO1 AG18437 (PI: Keller) 2002-2006
NIH/NIA
"Involvement and Characterization of Proteasome Inhibition in Brain Aging"
The goal of this project is to define the changes in proteasome biology that occur in the CNS during aging.

Hereditary Disease Foundation (PI: Keller) 2003-2005

"The role of p53 in Huntington's disease"

The goal of this project was to define the contribution of p53 to yeast and neural cell models of HD.

Alzheimer's Association (PI: Keller) 12/1/06-11/31/09
Alzheimer's Association Independent Investigator Award
"HDAC inhibitors as therapeutics towards Beta amyloid toxicity in vitro and in vivo"
The goal of this project is to look at the effects of histone deactylase inhibitors towards the toxicity of beta amyloid in neuron cultures and the APP/PS1 transgenic mice. No overlap with proposed studies.

1R21 NS052761 (Keller-PI) 5/1/06-4/31/08
NIH/NINDS
"Genetic basis for alpha-synuclein toxicity"
The goal of these studies is to use the yeast model to understand which genes increase or decrease alpha-synuclein aggregation and alpha-synuclein toxicity.

P01 DA19398 (Keller co-PI) 8/1/05 - 7/31/10
NIH/NIDA
Opiate drug abuse and CNS vulnerability to HIV (Project 3:"Synergistic Activation of Microglia by Opioids and HIV Virotoxins")
The objectives of this Program Project grant are to determine the extent to the mechanisms by which opiate-based drugs of abuse exacerbate the neurological consequences of HIV-1 infection in the brain. Neuronal, astroglial, and microglial responses will all be measured and integrated into a physiological continuum.

P20 RR15592 (Keller co-PI) 9/15/05 - 6/30/09
NIH/NCRR
Center of Biomedical Research Excellence in Women's Health (Project 3: "Estrogen, the Proteasome, and HIV"). The objectives of this project are to determine the ability of and the mechanisms whereby estrogen modulates Tat-mediated HIV-1 replication in brain cells. The specific role of the proteasome in these parameters will also be elucidated. No overlap.

5R01AG012694 (Keller co-PI) 6/1/06-05/31/11
NIH/NIA
Canine as an animal model of human aging
This project investigates the changes in cognition and neurochemical alterations which occur in the aging canine. Studies are aimed at elucidating the basis for human brain aging, using the canine model. Studies with antioxidant diets are aimed at understanding the role of oxidative stress as a mediator of age-related pathologies.

R21 DE018332 (Keller co-PI) 8/01/07-7/31/09
NIH/ NIDCR
Anti-Retroviral Therapy on Oral Epithelial Cell Biology
This project examines the effect of anti-retroviral therapy on epithelial cell function including proteasome function, inflammation, and saliva production. These studies will help understand the interplay between anti-retroviral therapy and proteasome function, inflammation, and saliva production.

1RO1 AG025771 (Keller-PI) 2/01/08 - 7/31/13
NIH/NIA
"Dietary restriction, aging and the proteasome"
This project quantified the changes in proteasome function in non-CNS tissues (immune, skeletal, hepatic, cardiovascular systems) that occur in response to aging and dietary restriction. Additionally, this grant will examine the effects of proteasome inhibition on non-CNS cells, and determine which features of aging are mediated by proteasome inhibition.

1RO1 AG029885 (Keller-PI) 3/15/08 – 8/31/13
NIH/NIA
"Dietary restriction and proteasome mediated protein degradation in the CNS"

This project quantified the changes in proteasome function in the CNS that occurs in response to aging and dietary restriction. Additionally, this grant will examine the effects of proteasome inhibition on CNS cells, and determine which features of aging are mediated by proteasome inhibition in the CNS.

2PO1 AG005119 (Keller –PI of project 3) 4/01/08 - 3/31/14
NIH/NIA (co-PI of whole PPG)
"The RAGE and beta amyloid oxidative stress toxicity"
This project of the PPG examines the mechanism by which RAGE signaling contributes to A-beta induced toxicity and oxidative stress.

R21 NS077482-01 (Keller-PI) 9/01/11 – 8/31/13
NIH/CMND
"Dietary and visceral fat regulate vascular amyloid pathogenesis"
This project will test the hypothesis that dietary induced obesity promotes alterations in Aβ pathology, and corresponding increases in the downstream components of Aβ pathogenesis, that are dependent in part on increases in visceral adiposity. Secondly, this project will test the hypothesis that increased levels of visceral adiposity are sufficient to promote Aβ pathology, and the downstream components of Aβ pathogenesis.

U01 AG029824 (Keller-Sub I) 3/1/11 – 8/31/16
NIH/Wake Forest University Health Sciences
"ASPirin in Reducing Events in the Elderly-ASPREE"
The primary objective is to determine whether low-dose aspirin prolongs life, or life free of dementia, or life free of significant, persistent physical disability in the healthy elderly.

LSU ICON (Keller-PI) 5/01/12 – 4/31/14
"Determining the impact of diabetes on health and independence of individuals with dementia"
This project uses the medical records of the LSU Healthcare System to understand the impact of dementia and diabetes on the elderly in Louisiana.

8P20GM103424-11 (Keller, Mentor) 5/01/12 – 4/30/15
NIH IDeA Networks of Biomedical Research Excellence (INBRE)
"Targeting beta amyloid clearance as therapeutic approach for Alzheimer's disease"
This project uses in vitro and in vivo models of Alzheimer's disease to understand beta-amyloid biology.

1R15NS091934-01 (Keller, Co-PI) 4/1/15-6/30/17
"Targeting cerebrovascular endothelial cells as a therapeutic approach for amyloid pathogenesis"
This project focuses on using high throughput screening as a tool for identifying therapeutics for cerebral amyloid disorders.

Previous Pharmaceutical Trials

Merck MK-0261 (Keller, PI) 3/30/12 – 8/31/13
"A study to assess the feasibility, sensitivity and specificity of CSF collection for assays of Alzheimer's disease biomarkers"

Sanofi (Keller, PI) 3/22/11-3/21/13
"A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effect on cognitive performance, safety, and tolerability of SAR110894D at the doses of 0.5 mg, 2 mg, and 5 mg/day for 24 weeks in patients with mild to moderate Alzheimer's Disease on stable donepezil therapy"

FutureCeuticals (Keller, PI) 05/1/14-11/15/14
"Feasibility and Safety of CFE towards brain function and brain activity in non-demented elderly subjects"

Merck 000318 (Keller, PI) 5/1/14-6/30/15
"A Clinical Trial to Assess Cognitive Function by Repeated Computerized Testing in Patients with Mild Alzheimer's Disease Treated with Donepezil"

Avie Nutraceuticals, LLC (Keller, PI) 12/1/14-5/31/16
"Feasibility and Safety of Avie 100 towards brain function and brain activity in non-demented elderly subjects."

EnVivo (Keller, PI) 12/1/13-11/30/15
"A randomized, double blind, placebo controlled, parallel group, 26 week, phase 3 study of two doses of EVP-6124 or placebo in subjects with mild to moderate Alzheimer's disease currently or previously receiving an acetylcholinesterase inhibitor medication"

Merck EPOCH (Keller, PI) 3/30/12 – 4/28/16
"A randomized, placebo controlled, parallel-group, double blind efficacy and safety trial of MK8931 in subjects with mild to moderate Alzheimer's disease"

Toyama/ADCS (Keller, PI) 8/1/14-7/31/17
"A phase 2 multi-center, randomized, double blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of T-817MA in patients with mild to moderate Alzheimer's disease"

Neurodyne (Keller, PI) 6/1/15-12/31/2106
"Pilot study to determine the feasibility, safety, and tolerability of a combination of essential fatty acids, panax ginsing extract, and green tea catechins, on cognitive function and functional MRI activity in middle age and older healthy adults"

Neurim (Keller, PI) 6/1/16-12/31/2017
"Randomized, double blind, placebo-controlled, parallel group, dose-ranging study of piromelantine in patients with mild dementia due to Alzheimer's disease"

Roche/Genentech (Keller, PI) 4/1/14-3/31/18
"A phase III, Randomized, double-blind, placebo-controlled, parallel-group, multicenter efficacy and safety study of gantenerumab in patients with mild Alzheimer's disease".

Merck APECS (Keller, PI) 11/1/13-6/1/17
"A randomized, placebo controlled, parallel-group, double blind efficacy and safety trial of MK8931 in subjects with prodromal Alzheimer's disease"

Axovant (Keller, PI) 4/1/16-12/31/2017
"A Phase 3, double-blind, randomized study of RVT-101 versus placebo when added to existing stable donepezil treatment in subjects with mild to moderate Alzheimer's disease"

Previous NIH Randomized Controlled Trials

U01 AG029824 (Keller-Sub I) 3/1/11 – 8/31/16
NIH/Wake Forest University Health Sciences
"ASPirin in Reducing Events in the Elderly-ASPREE"
The primary objective is to use a randomized clinical trial approach to determine whether low-dose aspirin prolongs life, or life free of dementia, or life free of significant, persistent physical disability in the healthy elderly.

R21 AT007170 (Keller-PI) 9/30/12-6/30/14
NIH/NCAAM
"Walking interventions, cognitive remediation, and mild cognitive impairment"
The focus of this randomized clinical trial project is to test the hypothesis that implementation of a rigorous program consisting of both a walking intervention and cognitive remediation program, will have significant and beneficial effects towards cognitive decline and gait in the non-disabled elderly individuals with MCI.

Current Pharmaceutical / NIH Trials

1R01AG049749-01A1 (Keller, PI PBRC Site) 1/15/2016-11/30/2022
NIH/NIA
"Exercise and intensive vascular risk reduction in preventing dementia"
This Project examines the ability of pharmacological and non-pharmacological interventions to reduce risk for dementia.

NIH/ADCS/Eli Lilly (Keller, PI) 11/1/2015-10/31/2020
"A4 Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)"
This Project examines the ability of pharmacological interventions to reduce risk for dementia.

SUVN (Keller, PI) 6/15/2017-12/31/2019
A phase 2A multicenter, randomized multicenter, randomized, double-blind, parallel group, 26 week, placebo controlled study of 50 mg and 100 mg of SUVN-502 in subjects with moderate Alzheimer's disease currently treated with donepezil hydrochloride and memantine hydrochloride.

Janssen (Keller, PI) 6/1/2017-12/31/2023
"A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Study Investigation the Efficacy and Safety of JNJ-54861911 in Subjects who are Asymptomatic at Risk for Developing Alzheimer's Dementia"

Eisai (Keller, PI) 8/15/2017-12/31/2021
A placebo-controlled, double bling, parallel group, 24 month study to evaluate the efficacy and safety of E2609 in subjects with Early Alzheimer's disease.

PBRC Foundation (Keller, PI) 10/1/2018-11/31/2019
Reducing Sedatives and Anticholinergics in elderly polypharmacy patients

Pending Pharmaceutical Clinical Trials

Roche (Keller, PI) 11/2018 12/31/2023
A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel group, efficacy and safety study of crenezumab in patients with prodromal to mild AD.

Eli Lilli (Keller, PI) 12/2018-12/31/2020
Multiple-dose, dose-escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of LY3303560 in patients with mild cognitive impairment due to AD or mild to moderate AD.

Axsome Therapeutics (Keller, PI) 11/2019- 10/31/22
A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of AXS-05 for the Treatment of Agitation in Subjects with Dementia of the Alzheimer's Type

NIH (Keller. PI PBRC site). 3/2019-2/28/2024
Metformin for Alzheimer's prevention

PROFESSIONAL SERVICE

Grant Review

2001-2010	National Advisory Council for American Federation of Aging Research
2001-2010	John Douglass French Alzheimer's foundation
2001-2011	American Federation of Aging Research
2001-present	Alzheimer's Association
2002-present	International Italian Telethon Research Foundation

2002-present	Board of Directors for Kentucky Chapter of Huntington's disease Society
2003-present	Burroughs-Wellcome Trust
2004	NIH Special Emphasis Panel for ALS (ZNS1/SRB E-06) 1/22/04
2004	Advisory Council for New Zealand Neurological Association
2005	NIH CDIN (3/23/05)
2005	NIH CDIN (6/22/05)
2005	NIH PPG review (ZAG1 ZIJ - 4(O3)) 7-19-05
2006	NIH ZNS1 SRB-G 05 (3/8/06)
2006	NIH CDIN (3/18/06)* appointed as regular member for 3yr appointment
2006	Advisory Council for Catalan Agency for Health Technology Assessment and Research (Spain)
2006-present	James and Esther King Biomedical Research Program (Florida)
2006	NIH CDIN (Oct 26-27)
2006	NIH BCDN Members SEP (Nov 2-3)
2006	NIH RoadMap (HTS screening) (Nov 14-16)
2007-present	Reviewer for the UKADC pilot grant review group
2007	NIH CDIN (June 27-28)
2007	NIH BDCN Members conflict (SEP) (July 18)
2007	NIH ZRG1 High-throughput screening SEP (July 18-19)
2007	NIH BDCN Members conflict (SEP) (Oct 11)
2007	NIH CDIN (Oct 11-12)
2008	NIH CDIN (Jan 30-Feb 1)
2008	NIH ZRG BST-J (50) HTS assay for MLPCN
2009	NIH ZRG1 MDCN-G(02)-SEP Neurodevelopment & Neurobiology
2009	NIH CMAD (June 11-12)
2009	NIH Challenge Grant review (June 16-18)
2009	NIH ZAG1 ZIJ-7 (O3) (August 19)
2009	NIH CMAD (October 7-9)
2010	NIH NOMD (February 4-5)
2010-2013	NIH Cellular Mechanisms in Aging and Development (CMAD), full Member
3/1/11-2/28/15	American Heart Association Grant Review Committee (Basic & Clinical / Translational Division), Member
2012	LSU Initiative for Maximizing Student Diversity (IMSD) program Advisory Board
2014	Military Relevant Peer Reviewed Alzheimer's Disease Research Program (Feb 4-6,2014)
2014	Alzheimer Association Translational Research Funding Review Committee
2015	NIH CMAD study section (Feb 19-20,2015)
2016	NIH NOMD study section (Oct 24-25, 2016)
2017	NIH Aging Systems and Geriatrics Study Sections (June 12-13, 2017)

2017 NIH Aging Systems and Geriatrics Study Section (Oct 16-17, 2017)
2018 NIH Aging Systems and Geriatrics Study Section (March 3-5,2018)
2018 NIH Aging Systems and Geriatrics Study Section (Oct 22-23,2018)

Journal Review

Editorial Board Appointments

2002--2004 *Journal of Alzheimer's Disease*
2003-present *International Journal of Biochemistry and Cell Biology*
2004-present *Ageing Research Reviews*
2004-present *Biogerontology*
2004-2008 *Biochimica et Biophysica Acta* (*Molecular Cell Biology Section*)
2005-2012 *Free Radical Biology and Medicine*
2005-2012 *Antioxidants and Redox Signaling*
2006-present *Free Radical Research*
2007-present *The Open Biology Journal* (Bentham Publishing)
2007-present *The Open Aging Journal* (Bentham Publishing)
2007-present *Journal of Neurochemistry*
2008-2011 *Journal of Biological Chemistry*
2013-present *Alzheimer's & Dementia: the Journal of the Alzheimer's Association*

Editor Appointments

2008-2014 *Associate Editor of Free Radical Research*
2009-present *Editor of Biochemica Biophysica Acta (Molecular Basis of Disease)* ***Impact Factor 5.1***
2013-present *Editor and Founder of Biochemica Biophysica Acta-Clinical*

Writing Group

2015 Appointed to the Look AHEAD Publications and Presentations Committee "P281 Effect of a Long-Term Intensive Lifestyle Intervention on Cognitive Function: The Action for Health in Diabetes Study" 3/20/15
2016 Appointed to the Look AHEAD Publications and Presentations Committee "P298 Predictors and correlates of cognitive changes in overweight and obese adults with type 2 diabetes" 5/8/16

INVITED PRESENTATIONS

Dr Keller gives over 50 Invited Presentations A Year on the Topics of Aging and Dementia. In addition to these various lectures he has given invited scientific presentations at the following locations.

1997 "Bioactive properties of lysophosphatidic acid" Plenary Session. International Conference on Bioreactive Lipids. Washington DC. 05/1997
2001 "Analysis of polyglutamine aggregation in living neural cells" HDSA Conference. Toronto CA. 11/2001.

2002 "Polyglutamine Expansion Alters Neural Preconditioning and Thermotolerance Response" Midwest Stress Response and Chaperone Conference. NorthWestern University. Chicago IL. 01/2002.

2002 "High thoroughput screening for Huntington's disease" Human Molecular Genetics, Chicago IL. 03/2002.

2002 NIA Group meeting "Proteomics in aging" 12/2002 Washington DC

2003 "Proteasomes and proteasome inhibition in neurodegeneration" Winter Brain Conference, Snowbird Utah 01/2003

2003 "Proteasomes and proteasome inhibition" Columbia University, Department of Neurology Seminar 2/27/2003

2003 "The Proteasome and brain aging" National Institute of Aging Summer Symposia Buck Institute, Novato Ca. 05/08/2003

2003 "Proteasomes and proteasome inhibition in neurodegeneration" Dept. of Physiology, University of Kentucky, 9/24/2003

2003 "Proteasomes and oxidative stress" Dept of Toxicology, University of Kentucky 10/8/2003

2003 "Proteasomes and proteasome inhibition in the brain" Plenary session at the Society for Neuroscience meeting. New Orleans, LA 11/12/2003

2003 "Proteasome inhibition and oxidative stress" International Gerontology and Neuropharmacology Meeting. San Juan Puerto Rico 12/12/2003

2004 "Proteasomes and beta amyloid toxicity" Expert Workshop on the Biology of Chromosome 21 genes: towards Gene-Phenotype correlations in Down Syndrome. Hosted by NINDS, Down Syndrome Society and the Coleman Institute for Cognitive Disabilities. Washington DC 06/11- 06/14/2004

2004 "Role of p53 in Huntington's disease" Hereditary Disease Foundation Cambridge MA 08/12- 08/14/2004

2004 "Proteasomes, oxidative stress, and caloric restriction" National Institutes of Aging, Baltimore MD 8/30- 8/31/04

2004 "Oxidative stress and neurodegeneration" University of Camerino, Camerino Italy 9/20/04

2004 "Proteasomes and oxidative stress" University of Camerino, Camerino Italy 9/21/04

2005 "Proteasomes, oxidative stress, and neurodegeneration" Case Western Reserve Department of Pathology. Cleveland OH 1/22/05

2005 "Proteasomes, oxidative stress, and aging" Hunter College, Department of Biological Sciences, New York 3/7/05

2005 "Proteasomes and models of neurodegenerative disease in yeast" University of Cologne, Cologne Germany 11/8/05

2005 "Oxidative stress, protein oxidation, and proteasomes" University of Dusseldorf, Dusseldorf, Germany 11/10/05

2006 "Protein degradation, synthesis, and oxidation in aging and AD" University of Texas Health Science Center, San Antonio TX 3/8/06

2006 "Proteasomes, protein synthesis, and age-related disorders" Invited Symposia Lecture. European Dutch Federation of Neurosciences. Amsterdam 6/12/06

2006 "Proteasomes, protein synthesis, and oxidative stress" Invited Symposia Lecture. Society for Free Radical Biology and Medicine. Davos Switzerland 8/12/06

2006 "Protein synthesis, degradation, and oxidation in aging and age-related disease" National University of Singapore, Singapore 9/8/06

2006 "Protein synthesis, degradation, and oxidation in aging and age-related disease" Pennington Research Center, LSU : 9/27/06

2007 "Protein degradation and synthesis in neurodegenerative disease" Temple University, Philadelphia PA: 3/24/07

2007 "Oxidative Stress and Neurodegeneration" Oklahoma Medical Research Foundation, Oklahoma City, OK 9/13/08

2008 "Alzheimer's Disease: What we know, What we need to know" Alzheimer's Services, Baton Rouge, LA 11/14/08

2009 "Alzheimer's Disease Research: Where we are now" Alzheimer's Association Dementia Care Conference, Baton Rouge, LA 3/6/09, New Orleans, LA 3/27/09 & Lafayette, LA 05/01/09

2010 "Aging and diet effects on proteasomes and oxidative stress in the heart" Plenary Session, Keystone Symposia, Keystone, CO 03/02/10

2010 "Contribution of Proteasome Inhibition to Oxidative Stress and Aging" Experimental Biology Meeting, Anaheim CA 04/28/10

2010 "Understanding and Curing Alzheimer's disease - Where are we? Where are we headed? University of Louisiana, Lafayette-College of Nursing and Allied Health Professions Continuing Nursing Education Program, Lafayette, LA 09/24/10

2010 "Alzheimer's findings in Louisiana" Chronic Care Management Conference, New Orleans, LA 10/19/10

2010 "Alzheimer's findings in Louisiana", Homecare Association of Louisiana & Louisiana Assisted Living Association Annual Meeting, Baton Rouge, LA 11/3/10

2012 "Physical activity/performance, falls, and the development of dementia in the elderly", Society for Behavioral Medicine Master Lecture, New Orleans, LA 04/13/12.

2012 "Links between Lifespace, Physical Performance, Gait, Frailty, and Cognitive Decline in the Elderly", 7th International Academy on Nutrition and Aging, Albuquerque, NM 07/12/12.

2012 "One scientist study of aging in yeast, rodents, and humans" Invited Lecture Barshop Institute, San Antonio TX10-24-12

2013 "Studies in mice and man: Understanding the regulation of brain aging," Invited Lecture, Expert Mentor Program, Gene Center, Hunter College, New York, 6-21-13

2013 "Aging and Brain Resiliency" Keynote Speaker University of Southern Alabama, Mobile Al 10-4,13

2014 "Dementia and Dementia Caregivers" Keynote Speaker University of Southern Alabama, Mobile Al 10-29-14

2015 "Latest Findings on Mild Cognitive Impairment Detection and Management: Role of Technology" Aging Life Care Association (South Central Chapter), Tulsa, OK, 11/5/2015

2015 "Latest Trends and Developments in Translational Research" Joyce Goodwin Lecture, Auburn University, December 2015

2017 "Latest in technology for dementia diagnosis, management, and prevention" Senior Choice Health Care, Pheonix AZ April 2017

2017 "Latest in technology for dementia diagnosis, management, and prevention" Aging Life Care Association Dallas TX May 2017